Completed Enrollment

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

I3Y-MC-JPEG -

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Prostate Cancer
What the trial is testing?
Abemaciclib, Abiraterone, LY2835219, Prednisone, Prednisolone
Could I receive a Placebo?
No
Enrollment Goal
900
Trial Dates
Apr 14, 2022 - Oct 2027
How long will I be in the trial?
Your participation in this trial could last up to 60 months, depending on how you and your tumor respond.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have prostate cancer that has spread to other parts of the body and is expected to respond to hormone treatments designed to lower testosterone (metastatic hormone-sensitive prostate cancer)

  • Participant must have cancer that has spread to the bones significantly and/or to the viscera, which are the soft internal organs of the body (for example, the lungs, liver, and the organs of the digestive system)

  • Participant must have adequate organ function

Participants Must Not:

  • Participant must not have received prior treatment with abemaciclib or other drugs that work in the same way

  • Participant must not have received previous treatment(s) for metastatic cancer except for up to 3 months of androgen deprivation therapy (ADT) or up to 6 courses of chemotherapy with ADT

  • Participant must not have serious or uncontrolled medical conditions such as certain cardiovascular disorders, active or chronic liver disease, uncontrolled hypertension, active systemic infections or currently treated for cancer other than prostate

  • Participant must not have prostate cancer that has spread to the central nervous system that is not treated and stable

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources

Prostate Cancer Research

By volunteering to take part in Prostate cancer clinical trials, you may be able to play an important role in the research and development of potential new treatments and medicines. We understand that when you or a loved one take part in a clinical trial, it is a big decision. It is important for you to understand why the research is being carried out and what taking part will mean for you. Learn more about Lilly

Prostate Cancer Research

Cancer Research

Lilly has been involved in cancer research for more than fifty years, working to improve the lives of people living with cancer. Learn more about cancer research at Lilly and how you can make an impact.

Learn More

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.